Omega-3 fatty acids not related to cardiovascular events
The results of prospective cohort studies suggest that fish and omega-3 fatty acids are associated with a low risk of fatal heart attack, sudden death and cardiovascular diseases in general. The Alpha Omega Trial showed that low-dose supplementation of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and of alpha linolenic acid (ALA) did not reduce major cardiovascular events in patients after heart attack.
What does this mean?
In contrast to earlier trials the omega-3 fatty acids did not reduce major cardiovascular events in the more recent trials. This may be a consequence of the current state-of-the-art drug treatment of elevated blood pressure, elevated serum cholesterol and the risk of thrombosis and results in a low absolute risk of cardiovascular events. In that situation it is much more difficult to show an effect of omega-3 fatty acids on major cardiovascular events than in the situation of a high absolute risk as observed in the earlier trials.
- Kromhout et al. N Engl J Med 2011;364:880-1
- Kromhout et al. N Engl J Med 2010;363:2015-26
- Geleijnse et al. Am Heart J 2010;159:539-46
- Giltay et al. Clin Chem 2003;49:652-5